Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin-paclitaxel versus capecitabine-oxaliplatin in neoadjuvant chemoradiation for esophageal cancer
IRCT20140903019036N3Phase 2Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Mar 2018
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of carboplatin, paclitaxel, capecitabine and oxaliplatin in esophageal cancer and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoint: Tumor regression grade. Started Mar 2018; status: completed.
02
Drugs
carboplatinpaclitaxelcapecitabineoxaliplatin
03
Conditions
esophageal cancergastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on IRCT20140903019036N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20140903019036N3.